PFIZER INC (PFE)

US7170811035 - Common Stock

28.27  +0.5 (+1.8%)

Premarket: 27.85 -0.42 (-1.49%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PFIZER INC

NYSE:PFE (5/8/2024, 7:11:59 PM)

Premarket: 27.85 -0.42 (-1.49%)

28.27

+0.5 (+1.8%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap160.08B
Shares
PE15.45
Fwd PE12.73
Dividend Yield6.05%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 83,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017

P: 12127332323

CEO: Albert Bourla

Employees: 83000

Website: https://www.pfizer.com/

PFE News

News Image26 minutes ago - The Motley FoolThis 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream

Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years.

News Image15 hours ago - ChartmillMost active S&P500 stocks in Wednesday's session

Which S&P500 stocks are the most active on Wednesday?

News Image19 hours ago - InvestorPlaceJust Say No to Drugs: 3 Pharma Stocks to Avoid

Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.

News Image19 hours ago - BloombergPfizer Agrees to Settle More than 10,000 Zantac Cancer Lawsuits

Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.

News Image20 hours ago - FinancialNewsMediaMitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END

News Image21 hours ago - FN Media Group LLCMitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example